Method of normalisation of thrombin time duration in newborn calves with iron deficiency anemia

FIELD: veterinary medicine.

SUBSTANCE: method of normalisation of the thrombin time duration in newborn calves with iron deficiency anemia consists in the fact that ferroglukin 150 mg (2 ml) intramuscularly is prescribed to newborn calves with iron deficiency anemia, twice with the interval of 4 days, cresacyne 5 mg/kg per day, including it in the scheme of watering for 4 days, starting simultaneously with the first injection of ferroglukin and gamavit intramuscularly once a day in the morning of 0.05 ml/kg for 4 days, starting simultaneously with ferroglukin and cresacyne.

EFFECT: acceleration of normalisation of thrombin time duration, enables to reduce the risk of vascular complications in newborn calves with iron deficiency anemia, to revitalise the herd, to reduce mortality, to maintain the volume and quality of the meat and dairy products obtained from animals.

2 ex

 

The invention relates to biology and veterinary medicine, namely to hamostaseologie.

The closest analogue of the proposed method to normalize the duration trombonology time of newborn calves with iron deficiency anemia can be considered EN 2462239 "the Way of normalization of thrombin time in newborn calves with iron deficiency anemia". In the prototype, as well as in the claimed method, is applied feroglobin, but as a single injection at the rate of 15 mg of iron per 1 kg of body weight of the calf, which is somewhat difficult to use this method because of the need for individualization of dosage. In addition, restistance used in the prototype glicerina ensures the occurrence of the claimed effect 50.0% later than in the claimed method. This is largely due to the fact that in the prototype in conjunction with the preparation of iron used only one metabolically active drug, are not able to cause that degree of stimulation of the metabolism, which causes the application at the same time the two drugs contained in the claimed method.

The aim of the invention is to normalise the duration of the thrombin time of newborn calves with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the normalization of thrombin time newborn calves with an iron deficiency is MIA assigned solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.

The method allows to normalize thrombin time of newborn calves with iron deficiency anemia after 4 days of treatment, taking it to the level characteristic for healthy calves. This allows newborn calves with iron deficiency anemia significantly reduce the risk of thrombotic complications, to improve the health of the herd, improving trophic tissues, and consequently to accelerate growth and to maintain productive animals.

The inventive method is carried out as follows.

For the diagnosis of newborn calves with anemia violations thrombin time undergoing assessment by the following methodology: the legislative Assembly of Barkagan, A. P. Momot. Basis of diagnosis of disorders of hemostasis. Moscow, 1999, the publishing house "Novamed-JSC - S. 82).

The principle of the method: determine the clotting time of the plasma under the influence of thrombin, standardized by activity in normal control plasma. Thrombin test characterizes the kinetics of the final stage of blood coagulation is the rate of conversion of fibrinogen to fibrin.

Used reagents: 1. Tris buffer, 0.05 M (or buffer Micah the Fox) pH 7.3 to 7.4. 2. A solution of thrombin in buffer activity 14-16 sec. The working solution of the reagent prepared in a plastic or silikonizirovannoj vitro and used the day of the examination. Stored at room temperature.

The research material is citrate plasma calf.

To 0.2 ml of the investigated plasma heated in a water bath at +37°C for 1 min, add 0.2 ml of thrombin (to which research should have a temperature not higher than +18-25°C). Immediately include stopwatch and note the clotting time.

The determination is performed manual or coagulometer.

The results are expressed in seconds, comparing the clotting time in normal control (reference) and investigated the plasma. Normal thrombin time (TV) is 14-16 sec. When iron deficiency anemia in calves observed acceleration of the TV.

When accelerating TV newborn calves with iron deficiency anemia need for treatment according to the stated method: solution feroglobin 150 mg (2 ml) intramuscularly, docrat with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.

Example 1. The newborn calf No. 74 with alsodefinitely anemia, 1st day of life, the body weight of 30 kg, the violation of erythropoiesis with signs of decreased levels of iron in his body, accompanied by a change of blood. Thus, the amount of hemoglobin he had made up 85.7 g/l, erythrocytes of 3.95×1012/l, siderocyte 1.5% at the level of iron in serum and 12.2 µmol/L. When the survey was detected acceleration of thrombin time (12 sec). The calf was assigned solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.

The next day after the end of treatment for calf normalization red blood count hemoglobin he was to 118.0 g/l, erythrocytes 4,72×1012/l when the number of siderocyte 7.5% and the level of iron in serum 21,0 µmol/L. The animal was achieved full normalization of thrombin time (15 sec), remaining stable thereafter.

Example 2. The newborn calf No. 44 with iron deficiency anemia, the 3rd day of life, weight 32 kg, the violation of erythropoiesis with signs of decreased levels of iron in his body, accompanied by a change pok the targets in the blood. Thus, the amount of hemoglobin it was 88.0 g/l, erythrocytes of 3.97×1012/l, sideration of 1.2% when the level of iron in serum of 11.9 µmol/L. When the survey was detected acceleration of thrombin time (11 seconds). The calf was appointed the solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.

The next day after the end of treatment for calf normalized red blood count hemoglobin he was 122,1 g/l, erythrocytes to 4.73×1012/l, sideration of 7.2% when the level of iron in serum 20,2 µmol/l, was achieved full normalization of thrombin time (16 seconds), remaining stable thereafter.

The use of the proposed method to normalize thrombin time in biology and veterinary medicine will help to avoid thrombotic complications in newborn calves with iron deficiency anemia, improve the herd, to reduce mortality, to keep the volume and the quality in the future from animal meat and dairy products.

The claimed method is tested on 45 newborn calves with iron deficiency anemia, which showed 100% Sluch the EV efficiency correction of iron deficiency anemia and thrombin time.

The method of normalizing the duration of the thrombin time of newborn calves with iron deficiency anemia, characterized in that simultaneously apply feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: veterinary medicine.

SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.

EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.

1 ex

FIELD: metallurgy.

SUBSTANCE: invention relates to casein succinylate of iron (III) wherein iron content varies from 4.5 wt % to 7 wt %, water solubility exceeds 92% while phosphorus-to-nitrogen ratio exceeds 5 wt %.

EFFECT: additionally, invention relates to production of iron (III) and to pharmaceutical composition containing casein succinylate of iron (III).

17 cl, 4 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to benzoimidazole derivatives of formula (I), as well as to their enantiomers, diastereoisomers, racemates and pharmaceutically acceptable salts, where n equals from 2 to 4, each of R1 substituents is independently selected from H, halogen, -C1-4alkyl, -C1-4pergaloalkyl, trifluoro-C1-4alkoxy, -NO2, -CN, CO2H, -OC1-4alkyl, -SC1-4alkyl, -S(C1-4alkyl)-Rc, -S(O)2(C1-4alkyl)-Rc, -S(O)-C1-4alkyl, -SO2-C1-4alkyl, -S-Rc, -S(O)-Rc, -SO2-Rc, -SO2-NH-Rc, -O-Rc, -CH2-O-Rc, -C(O)NH-Rc, -NRaRb, benzyloxy, phenyl, optionally substituted with one-two Rd, cyanobiphenyl-4-ylmethylsulpfanyl, cyanobiphenyl-4-ylmethanesulphonyl, or -S-(CH2)2-morpholine and two adjacent groups R1 can bind with formation of an aromatic 5-6-membered ring, optionally substituted with one methyl group or two atoms of halogen, optionally containing one or two S or N; Ra and Rb each independently represents C1-4alkyl, -C(O)C1-4alkyl, -C(O)-Rc, -C(O)CH2-Re, C1-4alkyl-Re, -SO2-Rc, -SO2-C1-4alkyl, phenyl, benzyl; or Ra and Rb together with a nitrogen atom, which they are bound with, form a monocyclic 5-6- membered heterocycloalkyl ring, optionally containing one heteroatom, selected from O; Rc represents -C3-8cycloalkyl, phenyl, optionally substituted with one-two Rd, benzyl, optionally substituted with one-three Rd; morpholine; Rd independently represents halogen, -OH, -C1-4alkyl or -C1-4perhalogenalkyl, trifluorine C1-4alcoxy, -OC1-4alkyl, or -O-benzyl optionally substituted with halogen, Re represents -C6heterocycloalkyl, optionally containing one or two of O or N atoms, optionally substituted with a methyl group; R2 and R3 both represent H, -CF3 or C1-3alkyl; each of Z represents a C or N atom, on condition that simultaneously not more than two Z represent N. The invention also relates to particular compounds, a pharmaceutical composition, based on formula (I) compound or a particular said compound, a method of treating diseases, mediated by propyl hydroxylase activity.

EFFECT: novel derivatives of benzimidazole, possessing an inhibiting activity with respect to PHD are obtained.

11 cl, 1 tbl, 186 ex

FIELD: biotechnologies.

SUBSTANCE: in a compound of formula ,

X means N or CH, R1 means hydrogen or cyano, R2 means saturated 4-7-membered residue of heterocyclyl, which is bound through a nitrogen atom that contains 1 to 2 heteroatoms chosen from N and O. Besides, heterocyclyl residue can be replaced with one substituent chosen from a group consisting of C3-C6-cycloalkyl, or with 1-4 fluorine atoms. The invention also refers to a method for obtaining compounds and to a medicine on their basis.

EFFECT: compounds can be used for production of a medicine suitable for being used in a method of treatment or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic diseases of kidneys and kidney failure.

16 cl, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at the simultaneous control of coccidiosis and iron deficiency. The compound comprises triazinones of formulas (I) or (II) wherein R1 means CF3-SO2- or CF3-S-, R2 means CH3, each R4, R5 and R6 means Cl (chlorine) or pharmaceutically acceptable salts thereof, and iron compounds (3+) specified in a group consisting of: multinucleated complex iron (III) and polysaccharide compounds and ammonium-iron (III) citrate. What is also declared is using the above compounds for producing drug preparations.

EFFECT: using the declared group of inventions is effective for the simultaneous control of coccidiosis and iron deficiency; it is accompanied by no adverse phenomena; the compound ingredients have no negative effects on each other; and their biological activity preserves.

17 cl, 15 tbl, 7 ex

FIELD: biotechnologies.

SUBSTANCE: invention relates to production of peptide derivative mimetic of EPO, with the formula: R1-R2-(CH2)n1-R3-(CH2)n2-R4-R5 (I) and its pharmaceutical salts, where R1, R5 are selected from cyclic peptides with sequences SEQ ID NO:5, 6, 7 and 8; n1, n2 represent integer numbers independently selected from 0-10; R2, R4 are selected from -CO or -CH2; R3 is selected from O, S, CH2, N(CH2)n3NHR6, NCO(CH2)n4NHR6, CHOCONH(CH2)n5NHR6, CHSCON(CH2)n5NHR6 or CHNHCON(CH2)n5NHR6; where n3 represents an integer number selected from 1-10, n4 is an integer number selected from 2-10, n5 represents an integer number selected from 2-10, R6 is selected from H or derivatives of metoxyethylene glycol. The produced peptide or its pharmaceutically acceptable salt is used within a pharmaceutical composition for treatment of disorders characterised with EPO deficit, low or defective population of erythrocytes.

EFFECT: invention makes it possible to produce an agonist of EPO receptor having higher biological activity compared to existing EPO mimetics.

15 cl, 2 dwg, 5 tbl, 19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, and namely to composition for prevention of iron deficiency anemia. Composition for prevention of iron deficiency anemia, which contains source of iron, source of copper, vitamins B1, B3, B6, B9, B12, ascorbic acid, extract from nettle leaves, extract from strawberry leaves, pantohematogen and auxiliary substances, with specified component ratio.

EFFECT: composition makes it possible to extend arsenal of methods for prevention of iron deficiency anemia and is effective.

4 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to iron-enriched food product, which contains iron source in form of solid particles, where particles include core, containing iron alginate, and external layer, which contains calcium alginate, where particles are obtained by method which includes the following stages: (i) formation of core, which contains iron alginate, by contact of bioavailable water-soluble salt of iron and one water-soluble alginate salt, (ii) contact of core with water solution of calcium salt, in concentration, which constitutes from 0.025 M to concentration of lower than solution saturation point, and (iii) separation of obtained solid product. Iron-enriched food product is applied for prevention and treatment of iron deficiency conditions of people.

EFFECT: solid particles are applicable for enrichment of food products with iron and is characterised by improved load ability, as well as possesses good stability under standard storage and application conditions.

11 cl, 9 dwg, 13 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and pulmonology, and concerns treating the patients with chronic obstructive pulmonary disease and ischemic heart disease and cardiac failure complicated by anaemia. For this purpose, pre-treatment haemoglobin and serum iron are evaluated. In that case, if the hemoglobin level is less than 110 mm/l, and the serum iron level is less than 5.85 mmol/l, the conventional treatment involving ACE inhibitors, beta blockers, diuretics, antiaggregants, statins as well as salmeterol and berodual, is added by prescribing an anti-anaemic therapy with Epocrin and Ferrum Lek. Epocrin is administered in a dose of 50 IU/kg subcutaneously 6 times a week; Ferrum Lek is administered in a dose of Fe 100 mg in 5 ml intravenously twice a week. The therapeutic course is 3 months.

EFFECT: this dose schedule of the preparations provides reducing a length of treatment by improving the central haemodynamics, and enhancing the respiratory function.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug encapsulation by non-solvent addition; the method is characterised by the fact that the above drug is presented by ferrocene, while a coating is carrageenan precipitated from a butanol solution by adding ethanol as a non-solvent and water at room temperature.

EFFECT: invention provides simplifying and accelerating the microencapsulation process, reducing the microencapsulation loss (higher weight yield).

2 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: veterinary medicine.

SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.

EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel derivative of ferrocene 1-(1,1,1,3,3,3-hexafluoro-2-ferrocenylprop-2-yl)-imidazole of formula

which shows an antitumour activity. Also claimed is a method of its obtaining (versions).

EFFECT: invention makes it possible to obtain the novel derivative of ferrocene, which can be applied in medicine for chemotherapy of oncologic diseases.

4 cl, 1 dwg, 2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a metal-salen complex derivative. The complex is represented as A-B-C, where A is the metal-salen complex, B is a bond zone, including at least one disulphide bond; and C is a functional molecule, consisting of at least one of enzymes, antibodies, antigens, peptides, amino acids, oliginucleotides, proteins, nucleic acids and medication molecules. The bond zone (B) includes a molecule of a cross-linking agent to form a cross-linking between the said metal-salen complex (A) and the said functional molecule (C). The said metal-salen complex (A) and the said molecule of the cross-linking agent are bound together via at least one disulphide bond; and the said molecule of the cross-linking agent and the said functional molecule (C) are bound together via at least one disulphide bond. The zone of the disulphide bond (B) results from the formation of a bond between a SH group, introduced as a substituent into the said metal-salen complex, and the SH group of the said functional molecule (C), or results from the formation of a bond between the SH group of the said metal-salen complex (A) or the said functional molecule (C) and the SH group of the cross-linking agent molecule. Also claimed is a method of obtaining the metal-salen complex derivative.

EFFECT: invention makes it possible to obtain the derivative of a metal-salen complex, characterised by an excellent output and stability.

3 cl, 2 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC-EEG) of the formula [(EEGS)2Fe2(NO)4] with the structural formula: , where R-S represents ethyl ether of glutathione containing a thiol group. The invention also relates to a composition for reducing functional disorders of myocardium subjected to hypoxia-reoxygenation which contains binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC EEG) as defined above and a pharmaceutically acceptable carrier. Also the use of DNIC-EEG is disclosed as antihypoxic agent.

EFFECT: reduction of hypoxic contracture, arrhythmias intensity and improvement of recovery of contractile function of the heart after reoxygenation.

3 cl, 1 tbl, 16 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely therapeutic dentistry and may be used for treating destructive forms of chronic periodontitis. That is ensured by administering a therapeutic preparation into a root canal. A sonic phoresis of the therapeutic preparation Beresh plus drops is preceded by coating the skin surrounding a causative tooth with a therapeutic mixture containing the preparation Beresh plus drops, 10% calcium gluconate and Vaseline oil. Thereafter, an emitter is used to process the area. The sonic phoresis is followed by a root canal obturation with calcium hydroxide. That is combined with administering ascorbic acid in a daily dose of 50-100 mg and the preparation Beresh plus drops 1 drop per 2 kg of body weight a day orally. The therapeutic course is 5-8 procedures.

EFFECT: invention enables arresting the inflammatory process in the aggressive lesion, reducing the number of complications and aggravations ensured by accelerating the repair processes in the apical aggressive lesion.

2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at the simultaneous control of coccidiosis and iron deficiency. The compound comprises triazinones of formulas (I) or (II) wherein R1 means CF3-SO2- or CF3-S-, R2 means CH3, each R4, R5 and R6 means Cl (chlorine) or pharmaceutically acceptable salts thereof, and iron compounds (3+) specified in a group consisting of: multinucleated complex iron (III) and polysaccharide compounds and ammonium-iron (III) citrate. What is also declared is using the above compounds for producing drug preparations.

EFFECT: using the declared group of inventions is effective for the simultaneous control of coccidiosis and iron deficiency; it is accompanied by no adverse phenomena; the compound ingredients have no negative effects on each other; and their biological activity preserves.

17 cl, 15 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and aims at conducting the endoscopic hemostasis in gastric-duodenal hemorrhages. For the purpose of conducting the hemostasis, the capillary hemostasis liquid "Hemostab" is used and accompanied by the injection compression infiltration of paravasal and periulcerous regions. "Hemostab" is introduced within a hemorrhage point that is followed by the argon-plasma coagulation.

EFFECT: using the declared group of inventions is effective for the hemostasis in gastric-duodenal hemorrhages; it has the positive local effect on the clinical course of the pathological process, reduces the length of recovery of the defects caused the hemorrhage with no toxicity of the above preparation and no allergies.

1 ex, 3 dwg, 6 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a complex compound of a magnetisable metal and salen. The complex compound is presented by formula (I) , wherein M represents Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir or Pt, and a-f and Y represents hydrogen, or -NHR3-, -NHCOR3 respectively provided a-f and Y are not hydrogen simultaneously, wherein -R3 represents a pharmaceutical molecule with R3 provides the transport of a charge equivalent to max. 0.5 electron (e); or by formula (II) , wherein M represents Fe, Y, a, c, d, f, g, i, j, 1 represent hydrogen respectively; b and k represent -NH2, h and e represent -NHR3, wherein -R3 represents taxol (paclitaxel), or M represents Fe, Y, a, c, d, f, g, i, j, 1 represent hydrogen respectively; b, e, h and k represent -NHR3-, wherein -R3 represent gemfibrozil. There are also presented a local anaesthetic, an antineoplastic agent, a complex metal molecule, an intermediate compound, methods for preparing the magnetic substance, methods for preparing the magnetisable compound. The present invention enables preparing the therapeutic agent using the magnetic properties of the complex of metal and salen for the purpose of magnetising the specific therapeutic agent by chemical binding of the therapeutic agent to the complex of metal and salen so that to deliver the therapeutic agent to an affected area.

EFFECT: preparing the complex compound of the magnetisable metal and salen.

16 cl, 20 dwg, 10 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, hypromellose, antiseptics and a consistency base in the following relation of ingredients, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000; metronidazole 0.00001-0.5; hypromellose 0.00001-0.5; antiseptics 0.00001-0.5; consistency base - the rest. Besides, the pharmaceutical composition contains antibiotics specified in a group: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains antiseptics specified in a group: boric acid, salicylic acid, hydrogen peroxide, chlorhexidine, ethanol, povidone iodine, silver nitrate, silver sulphadiazine in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains anesthesin or lidocaine as local anaesthetics in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains vitamin A or beta-carotene as food colorants in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains flavouring agents specified in a group of: tea tree oil, menthol oil, eucalyptus leaf oil in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000 as a consistency base.

EFFECT: more effective treatment.

7 cl, 11 ex

Up!